Recent Trading Performance for Crinetics Pharmaceuticals (CRNX)

Crinetics Pharmaceuticals (CRNX) has drawn investor attention after a period of weaker share performance, with the stock down about 3% over the past day, 6% over the past week, and 26% year to date.

At a share price of US$34.52, short term momentum has faded, with the stock down over recent weeks. However, the 1 year total shareholder return of 8.3% and 3 year total shareholder return of 58.5% point to a stronger longer term picture.

If recent volatility in Crinetics has you looking across healthcare, this could be a useful moment to scan for other specialised healthcare AI opportunities using the 40 healthcare AI stocks.

So with the stock recently weaker but longer term returns still positive, and the current share price at a steep discount to analyst targets, should you see CRNX as an undervalued biotech opportunity, or as a stock already pricing in future growth?

Most Popular Narrative: 58.1% Undervalued

Crinetics Pharmaceuticals most followed valuation narrative pegs fair value at about $82.43 per share, compared with the last close of $34.52, which is a steep gap to unpack.

The shift in acromegaly care toward patient friendly oral therapies, combined with PALSONIFY’s positioning as a potential first medical treatment after surgery, can expand treated patient numbers across switch, naive, previously discontinued and lost to follow up groups, which would directly influence revenue growth.

Want to see what kind of revenue ramp and margin shift that assumption is leaning on? The narrative stitches together aggressive growth, richer profitability and a premium earnings multiple to reach that fair value.

Result: Fair Value of $82.43 (UNDERVALUED)

However, this bullish setup still hinges on PALSONIFY prescriptions building meaningfully, as well as the wider pipeline avoiding delays or setbacks that keep losses elevated longer.

Next Steps

With sentiment split between the risks and rewards highlighted so far, this is a good time to review the data yourself and act decisively to form your own stance. Start with a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

Do not stop with one stock. Broaden your watchlist with focused stock ideas that match what you want from risk, quality and income.

• Target potential bargain opportunities by scanning 47 high quality undervalued stocks that combine quality fundamentals with prices that sit below their intrinsic estimates.
• Strengthen your portfolio core by checking solid balance sheet and fundamentals stocks screener (45 results) that emphasise financial resilience and durable business profiles.
• Get ahead of the crowd by reviewing a screener containing 22 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.